TABLE 3

Concerns About Treatment of NHL Patients with ⁹⁰Y-Ibritumomab Tiuxetan or ¹³¹I-Tositumomab Grouped by Positive (≥4) or Negative (<4) Predicted Future

	Mean rating
Concern	Positive future (≥4)	Negative future (<4)	P
⁹⁰Y-Ibritumomab tiuxetan administration is too complicated in general^{^*}	1.62	2.06	0.02
We have concerns about the radiation safety^{^*}	1.69	2.19	<0.01
We have concerns about the dosimetry procedure^{^*}	1.82	2.33	< 0.01
¹³¹I-tositumomab or ⁹⁰Y-ibritumomab tiuxetan take too much time from my practice in general^{^*}	1.94	2.39	< 0.01
Most nuclear physicians are not trained to administer potentially myeloablative therapies such as ⁹⁰Y-ibritumomab tiuxetan or ¹³¹I-tositumomab^{^*}	2.27	2.87	< 0.01
There might be unexpected late side effects of ¹³¹I-tositumomab or ⁹⁰Y-ibritumomab tiuxetan treatment (myelodysplastic syndrome)	2.30	2.44	0.45
Concerns exist that subsequent treatments will not be possible after ¹³¹I-tositumomab or ⁹⁰Y-ibritumomab tiuxetan administration	2.41	2.60	0.33
⁹⁰Y-ibritumomab tiuxetan or ¹³¹I-tositumomab therapy provides poor payment for the time and effort in the radiolabeling process	2.42	2.64	0.17
¹³¹I-tositumomab or ⁹⁰Y-ibritumomab tiuxetan treatment does not have enough reported randomized studies	2.49	2.52	0.74
¹³¹I-tositumomab administration is too complicated in general^{^*}	2.56	2.35	0.01
⁹⁰Y-ibritumomab tiuxetan or ¹³¹I-tositumomab therapy provides poor payment for the time and effort in the administration process	2.94	2.90	0.3
Oncologists and hematologists prefer to treat by themselves with nonradioactive compounds	3.48	3.38	0.2
¹³¹I-tositumomab or ⁹⁰Y-ibritumomab tiuxetan treatment is too expensive	3.51	3.27	0.18

↵* Considered significant difference.
P < 0.05 was considered significant.